Literature DB >> 29105752

Buprenorphine in Neonatal Abstinence Syndrome.

Walter K Kraft1.   

Abstract

Infants exposed in utero to opioids will demonstrate a withdrawal syndrome known as neonatal abstinence syndrome (NAS). Buprenorphine is a long-acting opioid with therapeutic use in medication-assisted treatment of opioid dependency in adults and adolescents. Emerging data from clinical trials and treatment cohorts demonstrate the efficacy and safety of sublingual buprenorphine for those infants with NAS who require pharmacologic treatment. Pharmacometric modeling will assist in defining the exposure-response relationships and facilitate dose optimization.
© 2017 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29105752      PMCID： PMC5739935          DOI： 10.1002/cpt.930

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  65 in total

Review 1.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Authors:  Richard P Mattick; Courtney Breen; Jo Kimber; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2014-02-06

2.  Disproportionality analysis of buprenorphine transdermal system and cardiac arrhythmia using FDA and WHO postmarketing reporting system data.

Authors:  Nelson E Sessler; Ekaterina Walker; Harsha Chickballapur; James Kacholakalayil; Paul M Coplan
Journal:  Postgrad Med       Date:  2017-01       Impact factor: 3.840

3.  Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome.

Authors:  Walter K Kraft; Susan C Adeniyi-Jones; Inna Chervoneva; Jay S Greenspan; Diane Abatemarco; Karol Kaltenbach; Michelle E Ehrlich
Journal:  N Engl J Med       Date:  2017-05-04       Impact factor: 91.245

4.  Toxicity of buprenorphine overdoses in children.

Authors:  Bryan D Hayes; Wendy Klein-Schwartz; Suzanne Doyon
Journal:  Pediatrics       Date:  2008-04       Impact factor: 7.124

5.  Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved.

Authors:  Louisa Degenhardt; Deborah Randall; Wayne Hall; Matthew Law; Tony Butler; Lucy Burns
Journal:  Drug Alcohol Depend       Date:  2009-07-15       Impact factor: 4.492

6.  ABM Clinical Protocol #19: Breastfeeding Promotion in the Prenatal Setting, Revision 2015.

Authors:  Casey Rosen-Carole; Scott Hartman
Journal:  Breastfeed Med       Date:  2015-12       Impact factor: 1.817

7.  Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4.

Authors:  K Kobayashi; T Yamamoto; K Chiba; M Tani; N Shimada; T Ishizaki; Y Kuroiwa
Journal:  Drug Metab Dispos       Date:  1998-08       Impact factor: 3.922

8.  Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome: A Pilot Study.

Authors:  Jason R Wiles; Barbara Isemann; Tomoyuki Mizuno; Meredith E Tabangin; Laura P Ward; Henry Akinbi; Alexander A Vinks
Journal:  J Pediatr       Date:  2015-09-11       Impact factor: 4.406

9.  Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny.

Authors:  Gregory L Kearns; Patricia K Robinson; John T Wilson; Deanna Wilson-Costello; Gail R Knight; Robert M Ward; John N van den Anker
Journal:  Clin Pharmacol Ther       Date:  2003-10       Impact factor: 6.875

Review 10.  Ethanol pharmacokinetics in neonates and infants.

Authors:  Elizabeth Marek; Walter K Kraft
Journal:  Curr Ther Res Clin Exp       Date:  2014-10-22
View more
  7 in total

1.  Stability-indicating LC-MS Method for Determination of Stability of Extemporaneously Compounded Buprenorphine Oral Syringes for Neonatal Abstinence Syndrome.

Authors:  Ankit Rochani; Vinh Nguyen; Robin Becker; Walter Kraft; Gagan Kaushal
Journal:  J Pediatr Pharmacol Ther       Date:  2021-05-19

Review 2.  Pharmacological and non-pharmacological treatments for the Neonatal Abstinence Syndrome (NAS).

Authors:  A K Mangat; G M Schmölzer; W K Kraft
Journal:  Semin Fetal Neonatal Med       Date:  2019-02-05       Impact factor: 3.926

3.  Mind the Gaps: Ontogeny of Human Brain P-gp and Its Impact on Drug Toxicity.

Authors:  Jean-Marie Nicolas; Elizabeth C M de Lange
Journal:  AAPS J       Date:  2019-05-28       Impact factor: 4.009

4.  Clearance of buprenorphine during pregnancy and neonatal outcomes.

Authors:  Jessica L Coker; Shona L Ray-Griffith; Cody McLeod; Xiaotong Han; Michael Mancino; Gregory L Kearns; Zachary N Stowe
Journal:  Arch Womens Ment Health       Date:  2021-04-16       Impact factor: 3.633

Review 5.  Neonatal opioid withdrawal syndrome: a review of the science and a look toward the use of buprenorphine for affected infants.

Authors:  Lori A Devlin; Leslie W Young; Walter K Kraft; Elisha M Wachman; Adam Czynski; Stephanie L Merhar; T Winhusen; Hendrée E Jones; Brenda B Poindexter; Lauren S Wakschlag; Amy L Salisbury; Abigail G Matthews; Jonathan M Davis
Journal:  J Perinatol       Date:  2021-09-23       Impact factor: 3.225

6.  Physiologic Indirect Response Modeling to Describe Buprenorphine Pharmacodynamics in Newborns Treated for Neonatal Opioid Withdrawal Syndrome.

Authors:  Tomoyuki Mizuno; Brooks T McPhail; Suyog Kamatkar; Scott Wexelblatt; Laura Ward; Uwe Christians; Henry T Akinbi; Alexander A Vinks
Journal:  Clin Pharmacokinet       Date:  2021-02       Impact factor: 6.447

Review 7.  Clinical pharmacology and dosing regimen optimization of neonatal opioid withdrawal syndrome treatments.

Authors:  Fei Tang; Chee M Ng; Henrietta S Bada; Markos Leggas
Journal:  Clin Transl Sci       Date:  2021-05-01       Impact factor: 4.689
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.